Podcasts about Retinal

Veonet Ireland has announced the introduction of DR.NOON AI Software by HeartEye Diagnostics - an AI-powered retinal screening system capable of detecting early signs of cardiovascular and diabetic vascular risk from a single, non-invasive eye retinal scan. At a time of high waiting lists for ophthalmology and cardiology, at 53,000 and 45,000 patients respectfully, DR.NOON offers a powerful preventive tool that can identify risk before symptoms appear. Built on clinically validated deep learning algorithms, DR.NOON AI software analyses subtle vascular patterns in the retina to uncover early indications of systemic disease, including hypertension, atherosclerosis, and microvascular changes associated with diabetes. Retinal screening to detect eye disease It delivers instant, AI-driven reports that match the outperform traditional methods in five-year cardiovascular risk prediction. This will include actionable insights for patients, identifying key risk indicators with personalised recommendations for lifestyle modification and disease management. With World Diabetes Day approaching on 14 November, the timing could not be more relevant. Diabetes remains a leading cause of vision loss among working-age adults, yet early detection can prevent over 90% of diabetes-related blindness, as it enables faster referral, timely treatment, and improved long-term outcomes for patients. Regular visits to your optometrist and enrolling in the Diabetic Retinal Screening Programme are as important as attending your diabetic clinic appointments. This is due to the increased risk of glaucoma, cataract and diabetic eye disease as a result of a diabetes diagnosis. "Diabetes, heart disease and vision loss are deeply interconnected, yet often diagnosed too late," explains Dr. Farah Ibrahim, Consultant Ophthalmologist at Veonet Ireland. "DR.NOON AI software changes that landscape - predicting cardiovascular risk for patients through a simple eye scan. This is preventive care in action: faster insights, earlier intervention, and ultimately, fewer patients joining already overstretched waiting lists." To mark its Irish debut, DR.NOON will be showcased at Veonet Ireland's upcoming CPD-accredited event, The Future of Vision: Emerging Advancements in Diabetic Eye Disease, taking place in Cork this Thursday, 13 November. The session will bring together optometrists, nurses, pharmacists and ophthalmic technicians to explore developments in diabetes eye management & experience how AI-driven innovation can reshape multidisciplinary diabetic eye care. You can learn more about the event, and reserve your spot in person or online, here. About Veonet Ireland Part of Veonet, Europe's leading ophthalmology group, Veonet Ireland is dedicated to delivering world-class, affordable, and accessible specialist eye care across Ireland. Founded by renowned ophthalmologists who recognised the value of sharing expertise, networking, and best practices, Veonet continues to advance the quality of ophthalmic care for patients across Europe. Veonet Ireland provides a supportive and positive environment where specialists and staff can grow both personally and professionally. Being a clinically led organisation, it empowers ophthalmologists to shape services and procedures in line with the highest clinical standards. See more breaking stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, Linke...

Please visit answersincme.com/SYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in retinal vein occlusion (RVO) discuss diagnosis and anti-VEGF treatment of the condition. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with RVO; Recognize the importance of early diagnosis to address the burden of RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

Please visit answersincme.com/SYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in retinal vein occlusion (RVO) discuss diagnosis and anti-VEGF treatment of the condition. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with RVO; Recognize the importance of early diagnosis to address the burden of RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

Drs. Kat Talcott and Sarwar Zahid join to discuss the December 2025 edition of Retinal Physician, including an overview of TKIs for retinal disease, the fluorinated gas and sustainability question, best practices for research clinical trial sites, and fellowship selection advice.

A groundbreaking retinal implant, PRIMA, is restoring central vision in patients with geographic atrophy (GA), an advanced form of macular degeneration that blinds roughly 1 million Americans. Unlike drugs that slow progression, this wireless neurostimulation system captures real-world images, projects them onto a subretinal chip, and electrically stimulates surviving retinal cells to mimic natural sight. Are we nearing a paradigm shift in how we treat vision loss?

In this week's Outspoken Review I'm reminiscing about the most embarrassing Bonfire Night of my life and why I thought it would cost me a very new relationship.I've also got some stunning beauty products to tell you about. There's the most INCREDIBLE lip oil with a perfect berry tint, the shower oil of dreams, the yummiest of fragrances and the best hair repair mask in the business.Enjoy xx

This episode is a reproduction of another Retina-Focused EyeNovation webinar series and a result of a special collaboration between the Canadian Retina Society and the Canadian Ophthalmological Society. Dr. Ioannis Dimopoulos of the University of Ottawa provides a comprehensive overview of Inherited Retinal Disorders, with a specific focus on various gene therapy approaches. He details the outcomes of his involvement in treatment approaches for Choroideremia. Dr. Bernard Hurley of the University of Ottawa moderates this webinar. 

Vidcast:  https://www.instagram.com/p/DQdpWA_kS0y/Age-Related Macular degeneration is the leading cause of adult blindness, but Stanford University research ophthalmologists have developed an electronic retinal implant that promises to restore sight to millions.  Their device, nicknamed PRIMA standing for photovoltaic retina implant microarray, includes a subretinal wireless implant and wearable video camera.  The camera, mounted on an eyeglass frame, detects an image.  That image is converted by a pocket processor into infrared laser light signals that are directed through the lens of the eye to the implant under the retina.  The implant, in turn, creates the neural electrical  signals that restore sight. The implant is entirely light-powered and requires no external power supply.This PRIMA system underwent a multisite, primary clinical trial at Stanford, the University of Pittsburgh, and Germany's University of Bonn.  A remarkable 27 of 32 implanted patients, 84%, regained the ability to read books, labels, and even street signs.  Some could even correctly make out some of the smallest lines on a standard eye chart.  The vision is black and white.Further refinement of the PRIMA chip is underway that promises a higher resolution and a refined grayscale.  No word yet as to whether this system will restore full color vision, but bioengineering ingenuity might just achieve that result…..someday soon.https://www.sciencedaily.com/releases/2025/10/251022023118.htm#google_vignettehttps://www.nejm.org/doi/10.1056/NEJMoa2501396#blindness #maculardegeneration #amd #prima #retinalimplant

Interview with Noemi Lois, MD, PhD, author of Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy. Hosted by Neil Bressler, MD. Related Content: Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy

Interview with Noemi Lois, MD, PhD, author of Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy. Hosted by Neil Bressler, MD. An earlier posted version of this podcast may not have stated clearly enough that in areas with loss of perfusion and loss of sensitivity at baseline which remained non-perfused during the follow up, the sensitivity deficit declined over time. This has been corrected in the podcast. Related Content: Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy

In this episode, we are joined by Drs. Thellea Leveque and Steven Yeh to discuss the myriad of considerations while managing retinal vasculitis.The discussants report no relevant financial disclosures.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AFV865. CME/NCPD/AAPA/IPCE credit will be available until October 22, 2026.Enhancing Diagnosis and Management of Retinal Diseases in Urgent Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AFV865. CME/NCPD/AAPA/IPCE credit will be available until October 22, 2026.Enhancing Diagnosis and Management of Retinal Diseases in Urgent Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AFV865. CME/NCPD/AAPA/IPCE credit will be available until October 22, 2026.Enhancing Diagnosis and Management of Retinal Diseases in Urgent Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AFV865. CME/NCPD/AAPA/IPCE credit will be available until October 22, 2026.Enhancing Diagnosis and Management of Retinal Diseases in Urgent Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AFV865. CME/NCPD/AAPA/IPCE credit will be available until October 22, 2026.Enhancing Diagnosis and Management of Retinal Diseases in Urgent Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AFV865. CME/NCPD/AAPA/IPCE credit will be available until October 22, 2026.Enhancing Diagnosis and Management of Retinal Diseases in Urgent Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Drs. Marianeli Rodriguez and Kat Talcott join to discuss the October 2025 edition of Retinal Physician, including inherited retinal disease treatment pipeline, gene therapy, and systemic therapy for sickle cell disease and retinopathy.

Robert Henderson, Consultant Ophthalmic Surgeon, Great Ormond Street Hospital and Moorfields Eye Hospital

Today's episode is all about visual thinking. We will explore vivid mental imagery and sensory processing. We will cover why Autistic individuals process detailed "pictures and movies" in the mind, exemplified by an anecdote of visualizing oak tree bark with tactile detail. Sensory challenges are highlighted, with a Bee Movie analogy illustrating the intense, efficient visual input. The Autistic sensory journey is described as fast but rocky, contrasting with non-autistic processing. Hyperconnectivity in visual pathways amplifies detail-oriented cognition, often leading to sensory overload.The episode explains how retinal ganglion cells and visual cortex hyperactivity enhance imagery in Autism. Kanner and Asperger's observations underscore visual memory strengths and technical interests, like pattern recognition. Increased mini-column density and reduced inhibition boost local processing but risk overload. Temple Grandin's insights show visual thinking's strengths in tasks like designing animal pathways, though social tasks challenge due to weaker prefrontal connectivity. The Autistic brain's wiring is framed as a unique strength, fostering intense, detailed cognitionTemple Grandin https://www.templegrandin.com/templegrandinbooks.htmlSensory Processing part 1 https://youtu.be/HTnFm8nY4oY?si=4Xso_tI_hMwhY_SXSensory Processing part 2 https://youtu.be/n31gyLb4ddM?si=CouaBhiVm8KixtG-Supplementing Relationships part 1 https://youtu.be/lglEGQ7pSlc?si=ncpla784LxOyUcQcSupplementing Relationships part 2 https://youtu.be/W8E2B7Qu4mg?si=UJE850SwvPmtOmEkDaylight Computer Companyuse "autism" for $50 off athttps://buy.daylightcomputer.com/autismChroma Light Devicesuse "autism" for 10% discount athttps://getchroma.co/?ref=autism00:00 Introduction to Visual Thinking02:00 Anecdote: Oak Tree Visualization; tree bark, tactile05:50 Sensory Processing Challenges; overload, information rate, avoidance09:40 Anecdote: Bee Movie Analogy; synchronized, intense, fast13:30 Autistic Sensory Rates/Speeds17:20 Eye Biology and Neural Relays; Retinal ganglion, SHANK3; Building Models details-to-general21:10 Magnocellular vs. Parvocellular Pathways; Motion, color, glutamate, GABA signaling25:00 Visual Cortex Hyperactivity; V1-V4, fMRI, synaptic pruning, details28:50 Mini-Columns and Sensory Overload; Neural units, inhibition, dense connections32:40 Kanner and Asperger Insights; Social isolation, technical interests, patterns38:39 Daylight Computer Company (and Daylight KIDS !), use "autism" for $50 discount40:54 Chroma Light Devices, use "autism" for 10% discount44:07 Reviews/Ratings & Contact InfoX: https://x.com/rps47586YT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

Drs. Akshay Thomas and Sarwar Zahid join to discuss the September 2025 edition of Retinal Physician, including port delivery system thoughts, AI for ROP, and suprachoroidal injections.

Join us for a first-look launch exclusive on Skin Anarchy as Dr. Ekta sits down with Keith O'Brien, the CEO of Hydrinity Accelerated Skin Science, to explore how regenerative medicine is transforming skincare. With a background in wound care, spine surgery, and oncology, Keith has applied the principles of rapid healing, pH balance, and inflammation control to aesthetics, creating products designed to repair, regenerate, and restore the skin.Hydrinity just launched their NEW RetaXome™ Daily Retinal Hydrator which is a proprietary, next-generation retinal-infused exosome that sets the new gold standard in regenerative retinoid therapy, offering high-dose, targeted delivery deep into the dermis — where it matters most.Hydrinity goes beyond facial care, addressing the unique needs of the body with formulas like the Encore Body Hydrator, which penetrates deeply with low molecular weight hyaluronic acid and high-dose antioxidants like Kakadu plum–derived vitamin C. Each product is designed with regenerative principles in mind: balancing pH, reducing inflammation, and supporting the skin's natural repair mechanisms.Science drives efficacy, but luxury isn't forgotten. Hydrinity formulations are clean, free from unnecessary dyes and fragrances, and crafted to feel as good as they perform.For Keith, consistency is key, and Hydrinity bridges the gap between biotech innovation and everyday beauty rituals. This episode offers a sneak peek into the future of skincare—where healing, science, and luxury intersect. Tune in to hear Keith O'Brien share the story behind Hydrinity, the science driving their formulations, and how regenerative medicine is reshaping both face and body care.To learn more about Hydrinity, visit their website and social mediaCHAPTERS:(0:02) Introduction & Guest Welcome(1:07) Hydrinity Origins & Wound Care Background(3:06) Expanding from Facial to Body Care(7:30) Scientific Principles: pH, Inflammation & Regenerative Medicine(11:20) Luxury Meets Science: Form, Function & Sensory Experience(16:11) Protocols, Estheticians & Evidence-Based Practice(19:01) Daily Habits & Importance of Body Skincare(21:18) New Product Launch: Hydrinity Retinol & Innovation(24:20) Retinol Therapy: Results, Stability & Gold StandardPlease fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

CME credits: 0.50 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Insights-and-Updates-New-Data-on-Next-Generation-Retinal-Treatments/36107/ Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice. =

CME credits: 0.50 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Insights-and-Updates-New-Data-on-Next-Generation-Retinal-Treatments/36107/ Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice. =

We discuss the current state of the Good Days charitable foundation with Dr. Michael Lai, MD. PhD, Retina Group of Washington, Assistant Clinical Professor, Georgetown University School of Medicine

Claudia Muehlenweg helps people naturally improve their vision and ditch their glasses for good. She also explores how unresolved emotions can affect eyesight and healing.New episodes of Welcome to Wellness released every Friday!Not listening on Spotify? Show notes at: https://www.ashleydeeley.com/w2w/claudiaeyehealthEpisode brought to you by: ⁠⁠⁠⁠⁠⁠⁠⁠⁠ARAZA Beauty⁠Episode brought to you by:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ VieLight⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Code: DEELEY10Episode brought to you by:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dry Farm Wines⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 07:36: Understanding Vision: The Role of Stress and Mindset11:21: Nutrition for Eye Health: The Power of Food12:55: The Importance of Eye Exams and Technology16:22: Surgery vs. Natural Vision Improvement22:43: Strengthening Vision Post-Surgery24:22: Practical Tips for Better Vision30:19: What Harms Our Eyes: Bad Habits and Practices31:17: Anxiety is related to myopia31:35: Anger is connected to farsightedness 31:58: Staring is awful for your eyes (make sure to blink!)32:32: The Impact of Blue Light on Vision36:39: Emotional Connections to Vision Problems43:07: Exploring Common Eye Diseases48:59: Cataract Surgery: Insights and Considerations51:36: Addressing Stargardt's Disease and Other Retinal Issues56:03: Encouraging Healthy Vision in Children57:06Aging and Vision: What You Need to KnowWhere to find Claudia:WebsiteLinkedInWhere to find Ashley Deeley:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠hello@ashleydeeley.com

What do retinal scans reveal about diabetes complications? In Part 2, Vinod Patel shares insights from his clinical research on diabetic retinopathy, including key risk factors, the impact of hypertension, and the future of screening using advanced imaging tools. A must-listen for clinicians and anyone curious about the eyes-diabetes connection.  Timestamps: 00:30 – Risk factors  02:17 – Drug treatments  03:01 – Retinal ischaemia   06:12 – Retinal imaging 

Can a simple vitamin or supplement help protect your sight? In this Macular Chats episode, we explore what current science tells us about nutritional approaches to support eye health, particularly in the context of age-related changes in the retina. Join Dr. Brian McKay and Dr. Murray Brilliant for a conversation about the widely used AREDS2 nutrient formula, as well as exciting new research into L-DOPA, a naturally occurring compound that may offer a stronger role for maintaining retinal health.

Drs. Safa Rahmani and Sarwar Zahid join to discuss the July 2025 Retinal Physician focusing on surgical cases and pearls. Relevant Financial Disclosures: None

Drs. Armstrong and Patel discuss current and emerging therapies for diabetes-related macular edema and wet age-related macular degeneration including anti-VEGF agents, the need for durability and reduced treatment burden, alternative delivery strategies, novel molecules, and gene-therapy.

In this episode, Dr. Steve Vargo chats with Dr. James Wood to discuss the underutilized potential of retinal imaging in eye care practices. They explore how retinal imaging, particularly widefield and ultra-widefield imaging, can significantly enhance patient education, boost compliance, and improve financial outcomes for practices. Dr. Wood shares practical tips for obtaining clearer images and strategies for increasing patient acceptance of screening procedures. The conversation also delves into the future of retinal imaging technology and its role in addressing the growing needs of an aging population.   Follow our Podcast on All Available Platforms Follow our Podcast on Instagram Follow IDOC on Facebook Follow IDOC on LinkedIn Watch our Podcast Video on YouTube

Drs. Modi and Dedania discuss GLP-1 receptor agonists and the retinal patient, including how GLP-1 receptor agonists work, benefits and risks in patients with retinal disease, and data from retrospective studies.

Drs. Durga Borkar and Yashaswini Singh join host Dr. Jay Sridhar to discuss their recent publication regarding private equity (PE) acquisition and access to retinal detachment surgery. According to the study, physicians in PE-acquired practices decreased their number of retinal detachment repairs by nearly 20% after acquisition, potentially negatively impacting access to care and patient outcomes. Discussed in today's podcast: Singh Y, Cardenas GB, Torabzadeh H, Whaley CM, Borkar D. Private Equity-Owned Physician Practices Decreased Access To Retinal Detachment Surgery, 2014-22. Health Affairs. 2025 May;44(5):589-596. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness. Built on the foundational science of Dr. Jean Bennett and leveraging the legacy of Luxturna, Magrath shares how Opus is developing subretinal AAV-based therapies targeting seven distinct mutations. He also explains why gene therapy is particularly well-suited to IRDs, shares compelling early clinical data, and discusses the promise of early intervention in preserving vision and enabling proper neural development. Subscribe to the podcast!Apple | Spotify | YouTube

Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape. www.ocutx.comPravin U. Dugel, MD Biography

Drs. Akshay Thomas and Sarwar Zahid join for a journal club podcast discussion of three recent high-impact articles:Visual Fields in Diabetic Retinopathy (https://www.ophthalmologyretina.org/article/S2468-6530(25)00208-8/abstract)Gender Differences in Case Volume (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2833393)Private Equity Practices and Retinal Detachment Volume (https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2024.01204?journalCode=hlthaff)Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

One of the challenges of delivering gene therapies to the eye is that once a subretinal injection is made, the therapy's distribution is confined to the margins of the pocket of fluid that is created, known as a bleb. Atsena, which is developing gene therapies for X-linked retinoschisis and Leber congenital amaurosis 1, uses its AAV.SPR technology that allows the gene therapy to spread laterally after injection. We spoke to Patrick Ritschel, CEO of Atsena Therapeutics, about the challenges of gene therapies for inherited retinal diseases, how the company's unique vector technology addresses this, and how it allows for safer and more effective delivery of gene therapies to the retina.

Unlock the fascinating connection between your eyes and your brain in this episode! Did you know that your retina can reveal early signs of brain disease—even years before symptoms appear? Discover how the eye, formed from brain tissue, acts as a window into your neurological and circulatory health. We'll dive into new research showing that simple eye exams may one day predict aging and age-related diseases like macular degeneration, diabetic retinopathy, hypertension, multiple sclerosis, Parkinson's, and even Alzheimer's.You'll learn about the role of the optic nerve, the latest breakthroughs in retinal imaging, and how changes in the eye might signal Alzheimer's up to 8–9 years before a diagnosis. Plus, we'll discuss why prevention—through diet, exercise, and targeted supplements—is more important than ever for protecting both your mind and vision.Ready to nourish your brain and eyes? Here's our recommended list of essential nutrients:Taurine, lutein, zeaxanthin, mesozeaxanthin, B vitamins, bilberry, ginkgo biloba, omega-3 fatty acids, alpha-lipoic acid, N-acetylcysteine, glutathione, bacopa, lycopene, selenium, zinc, and the mushroom lion's mane.Stay informed and take charge of your health—tune in and visit us at naturaleyecare.com for the latest tips on protecting your eyes and brain!

Today, we are joined by the esteemed Dr. Jay Chhablani, a distinguished professor of ophthalmology and vitreoretinal surgeon at the Department of Ophthalmology, University of Pittsburgh. As the Director of Clinical Research at the UPMC Vision Institute, Dr. Chhablani stands at the forefront of cutting-edge advancements in eye care. Embark on a fascinating exploration as Dr. Chhablani, a retina specialist and surgeon, shares his wealth of knowledge on retinal diseases, ranging from bothersome floaters to age-related macular degeneration. Delve into the intricacies of ophthalmic surgeries, including the delicate art of retinal detachment repair. Press play to discover: The origins and prevention of eye floaters, along with effective treatment approaches. Conditions warranting surgical intervention for floaters. Navigating through complications associated with common ophthalmic surgeries and procedures. Distinguishing between the two primary forms of macular degeneration. The mechanics of novel drug therapies in slowing the progression of retinal diseases. Eager to learn more? Tune in and explore more at Jay Chhablani, MD | Department of Ophthalmology | University of Pittsburgh. Episode also available on Apple Podcasts: apple.co/30PvU9C

Dr. Nadia Khalil and Dr. Jean Bouchart discuss the diagnostic approach to intracerebral hemorrhage, the causes of cerebral small vessel disease, and the interpretation of biomolecular tests.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209796 

Drs. Ramsudha Narala, Kat Talcott, and Sarwar Zahid join to preview the June 2025 edition of Retinal Physician, focusing on GLP-1RAs and diabetic retinopathy, DRCR.net trial updates, CRAO protocol implementation, and early career advice for attendings. Relevant Financial Disclosures: None

Dr. Nadia Khalil talks with Dr. Jean Bouchart about the diagnostic approach to intracerebral hemorrhage, the causes of cerebral small vessel disease, and the interpretation of biomolecular tests.  Read the related article in Neurology® Resident & Fellow Section.  Disclosures can be found at Neurology.org. 

2521 Advancing Treatments for Inherited Retinal Diseases (May 21, 2025) Show Notes Research is key to fighting blinding eye diseases. Hosts Nancy and Peter Torpey talk with Jason Menzo, CEO of the Foundation Fighting Blindness, about advancing treatments for inherited retinal diseases, funding research initiatives, and launching new mental health resources to support individuals with … Continue reading 2521 Advancing Treatments for Inherited Retinal Diseases (May 21, 2025) →

Drs. Akshay Thomas and Sarwar Zahid join to preview the May 2025 edition of Retinal Physician, focusing on future developments in stem cells, microbots, artificial intelligence, and more.Relevant Financial Disclosures: None